CareRx Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Gewinn von CareRx wird voraussichtlich um 54.6% pro Jahr zurückgehen, während der Jahresumsatz um 4% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 12.5% pro Jahr sinken.
Wichtige Informationen
-54.6%
Wachstumsrate der Gewinne
-12.51%
EPS-Wachstumsrate
| Consumer Retailing Gewinnwachstum | 5.7% |
| Wachstumsrate der Einnahmen | 4.0% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 11 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narrativ-Update • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Narrativ-Update • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).
Narrativ-Update • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narrativ-Update • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.Narrativ-Update • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.Narrativ-Update • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.Narrativ-Update • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.Narrativ-Update • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).Narrativ-Update • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.Narrativ-Update • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.Narrativ-Update • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Analyseartikel • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Neues Narrativ • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Analyseartikel • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...Analyseartikel • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Analyseartikel • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...Analyseartikel • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...Analyseartikel • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • May 14
These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 415 | 8 | 30 | N/A | 3 |
| 12/31/2027 | 406 | 8 | 26 | N/A | 6 |
| 12/31/2026 | 385 | 6 | 16 | 33 | 7 |
| 3/31/2026 | 375 | 27 | 22 | 30 | N/A |
| 12/31/2025 | 370 | 26 | 23 | 31 | N/A |
| 9/30/2025 | 366 | 0 | 21 | 30 | N/A |
| 6/30/2025 | 366 | -2 | 23 | 32 | N/A |
| 3/31/2025 | 367 | -4 | 28 | 36 | N/A |
| 12/31/2024 | 367 | -5 | 30 | 38 | N/A |
| 9/30/2024 | 366 | -6 | 31 | 38 | N/A |
| 6/30/2024 | 367 | -7 | 27 | 34 | N/A |
| 3/31/2024 | 369 | -4 | 23 | 32 | N/A |
| 12/31/2023 | 371 | -5 | 19 | 27 | N/A |
| 9/30/2023 | 374 | -6 | 25 | 33 | N/A |
| 6/30/2023 | 378 | -7 | 30 | 38 | N/A |
| 3/31/2023 | 380 | -34 | 16 | 29 | N/A |
| 12/31/2022 | 382 | -34 | 9 | 22 | N/A |
| 9/30/2022 | 384 | -34 | -4 | 11 | N/A |
| 6/30/2022 | 358 | -36 | -5 | 10 | N/A |
| 3/31/2022 | 311 | -20 | -1 | 8 | N/A |
| 12/31/2021 | 263 | -23 | 0 | 7 | N/A |
| 9/30/2021 | 212 | -21 | 2 | 7 | N/A |
| 6/30/2021 | 187 | -24 | -6 | -3 | N/A |
| 3/31/2021 | 177 | -29 | -2 | 0 | N/A |
| 12/31/2020 | 162 | -18 | -2 | 0 | N/A |
| 9/30/2020 | 148 | -50 | -3 | -1 | N/A |
| 6/30/2020 | 134 | -47 | -2 | 0 | N/A |
| 3/31/2020 | 126 | -34 | -1 | 2 | N/A |
| 12/31/2019 | 125 | -46 | N/A | 6 | N/A |
| 9/30/2019 | 122 | -19 | N/A | 3 | N/A |
| 6/30/2019 | 119 | -20 | N/A | 4 | N/A |
| 3/31/2019 | 117 | -39 | N/A | 9 | N/A |
| 12/31/2018 | 119 | -35 | N/A | 7 | N/A |
| 9/30/2018 | 85 | -27 | N/A | 14 | N/A |
| 6/30/2018 | 97 | -23 | N/A | 12 | N/A |
| 3/31/2018 | 110 | -3 | N/A | 15 | N/A |
| 12/31/2017 | 122 | -4 | N/A | 16 | N/A |
| 9/30/2017 | 168 | -6 | N/A | 14 | N/A |
| 6/30/2017 | 170 | -3 | N/A | 24 | N/A |
| 3/31/2017 | 170 | -13 | N/A | 10 | N/A |
| 12/31/2016 | 167 | -18 | N/A | 2 | N/A |
| 9/30/2016 | 166 | -21 | N/A | 6 | N/A |
| 6/30/2016 | 166 | -34 | N/A | 3 | N/A |
| 3/31/2016 | 164 | -30 | N/A | 20 | N/A |
| 12/31/2015 | 161 | -35 | N/A | 29 | N/A |
| 9/30/2015 | 27 | -47 | N/A | 28 | N/A |
| 6/30/2015 | 60 | -48 | N/A | 22 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CRRXFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-54.6% pro Jahr).
Ertrag vs. Markt: CRRXFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-54.6% pro Jahr).
Hohe Wachstumserträge: CRRXFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: CRRXDie Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Canadian (4.5% pro Jahr).
Hohe Wachstumseinnahmen: CRRXDie Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRRX in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 09:35 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CareRx Corporation wird von 11 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |